Aligos Therapeutics (ALGS) Cash & Equivalents (2019 - 2026)

Aligos Therapeutics has reported Cash & Equivalents for 8 years, with the latest figure at $54.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 60.19% year-over-year to $54.9 million; the trailing twelve-month figure through Mar 2026 stood at $54.9 million (down 60.19% YoY), and the FY2025 full-year result was $18.3 million, down 50.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $54.9 million, up from $18.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $137.9 million in Q1 2025, with the low at $18.3 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $80.4 million across 5 years, with a median of $81.3 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 66.82% — and 2025, when it sank 80.25%.
• Aligos Therapeutics' Cash & Equivalents stood at $81.3 million in 2022, then jumped by 66.82% to $135.7 million in 2023, then tumbled by 72.74% to $37.0 million in 2024, then plunged by 50.53% to $18.3 million in 2025, then surged by 199.95% to $54.9 million in 2026.
• The last three Cash & Equivalents figures came in at $54.9 million (Q1 2026), $18.3 million (Q4 2025), and $99.1 million (Q3 2025), per Business Quant data.